Table 1.
Characteristics of study cohort patients
| Demographics | ||
| n | 260 | |
| Age | (yr)1 | 53 (44-60) |
| Sex | Male/Female n (%) | 157 (60)/103 (40) |
| Baseline viral characteristics | ||
| Genotype 1a/1b/1x | n (%)/n (%)/n (%) | 76 (29)/115 (44)/3(1) |
| Genotype 2/3 | n (%)/n (%) | 8 (3)/44 (17) |
| Genotype 4/5/6 | n (%)/n (%) | 11 (4)/1 (0.4)/2 (0.8) |
| Baseline viral load | (IU/mL)1 | 1.33 Mio. (414.750-3.4 Mio.) |
| Baseline viral load ≥ 800.000 IU/mL | n (%) | 169 (65) |
| Baseline viral load ≥ 6 Mio IU/mL | n (%) | 28 (11) |
| Special populations | ||
| LCi2 | n (%) | 89 (34) |
| Low platelets (≤ 100/nL) | n (%) | 56 (22) |
| Post Liver Transplantation | n (%) | 17 (7) |
| Patients ≥ 60 yr | n (%) | 72 (28) |
| Patients with MELD score ≥ 10 | n (%) | 25 (10) |
| Treatment history | ||
| Treatment experienced | n (%) | 144 (55) |
| Treatment regimens [thereof liver cirrhosis n (%)] | ||
| SOF PR | n (%)/LCi n (%) | 51 (20)/6 (12) |
| SOF R | n (%)/LCi n (%) | 10 (4)/4 (40) |
| SOF SMV | n (%)/LCi n (%)/R n (%) | 30 (12)/16 (53)/15 (19) |
| SOF DCV | n (%)/LCi n (%)/R n (%) | 81 (31)/42 (52)/12 (40) |
| SOF LDV | n (%)/LCi n (%)/R n (%) | 73 (28)/17 (23)/16 (22) |
| 3D | n (%)/LCi n (%)/R n (%) | 15 (6)/4 (27)/6 (40) |
| Baseline clinical chemistry | ||
| WBC | (/μL)1 | 5935 (4683-7670) |
| Hemoglobin | (g/dL)1 | 14.5 (13.1-15.6) |
| Platelets | (thousand/μL)1 | 174 (113-228) |
| Creatinine | (mg/dL)1 | 0.7 (0.6-0.8) |
| Total Bilirubin | (mg/dL)1 | 0.7 (0.5-1.0) |
| INR | INR1 | 1 (1-1) |
| ALT | IU/l1 | 67 (44-105) |
1
Data are presented as medians (interquartile ranges in parentheses);
2
By liver histology, Fibroscan (> 12.5 kPa), or by clinical diagnosis (e.g., esophageal varices, ascites, distinct ultrasound signs of portal hypertension or liver cirrhosis). 1x: Genotype 1, no subtype differentiable; LCi: Liver cirrhosis; MELD: Model of end stage liver disease; P: Pegylated Interferon; R: Ribavirin; SOF: Sofosbuvir; SMV: Simeprevir; LDV: Ledipasvir; DCV: Daclatasvir; 3D: Dasabuvir, Ombitasvir, and Paritaprevir/r; WBC: White blood cell count; INR: International normalized ratio; ALT: Alanine-aminotransferase.